Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Preventive Cardiology
Is there a role for CYP2C19 genetic testing in patients presenting with recurrent ACS in spite of adherence to plavix outpatient?
Related Questions
For patients with hypertension who have normal filling pressures following right cardiac catheterization, can hypertension still be attributed to volume overload?
Would you recommend starting a moderate-intensity statin in a patient under the age of 40 years old with HIV and a 10-year ASCVD risk estimate below 5%?
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
Is there a role of prophylactic aspirin in patients with incidental findings of aortic atherosclerosis but no history CAD or CVA?
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
What do you make of the results of the recent phase 2 RCT on Zerlasiran in terms of effectiveness at reducing lipoprotein (a) levels and the timing for when this will become readily available for patients who may benefit the most from it?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
For isolated and very high lipoprotein (a) levels (LDL of > 140, has an Lp(a) > 100) in a patient with no cardiac symptoms or risk factors, would you start lipid lowering treatment, such as with a PCSK9i if they develop statin intolerance?
What is your approach to medical management for cocaine-induced acute MI, and threshold to consider referral for coronary angiography in the setting of a markedly elevated troponin and LV systolic dysfunction?
How do you decide between obtaining routine, outpatient ETT versus stress TTE when screening for CAD, especially given insurance company preference on ETTs?
